The overarching goal of this project is to critically evaluate the efficacy of incorporating dietary guidance within multiple sclerosis (MS) care for improving long-term quality of life (QoL) compared to usual care. The primary objective of this study is to evaluate the effect of two dietary interventions (time restricted olive oil based (TROO) ketogenic and modified Paleolithic elimination) on MS QoL compared to usual care control (Dietary Guidelines for America), and the secondary objectives and the long-term effects on, motor function, low-contrast vision sensitivity, fatigue, mood, and disease activity assessed by brain imaging.
In the United States, MS affects nearly 1 million people with a 2.8:1 female to male ratio and the highest incidence rates among whites and African Americans. The economic cost of managing MS is substantial. In the U.S., the total medical costs for patients with MS increased from $116 million in 2002 to $198 million in 2013. MS is a chronic, neuroinflammatory, and neurodegenerative disease-causing symptoms of pain, fatigue, and changes in vision, cognition, and movement that greatly reduce quality of life (QoL) and the ability to maintain employment. The overarching goal of this project is to critically evaluate the efficacy of incorporating dietary guidance within multiple sclerosis (MS) care for improving long-term quality of life (QoL) compared to usual care. The primary objective of this study is to evaluate the effect of two dietary interventions (time restricted olive oil based (TROO) ketogenic and modified Paleolithic elimination) on MS QoL compared to usual care control (Dietary Guidelines for America), and the secondary objectives and the long-term effects on, motor function, low-contrast vision sensitivity, fatigue, mood, and disease activity assessed by brain imaging. The proposed study will consist of study participants attending 3 in-person site visits, months 0, 3, and 24, and online surveys every 3 months (months 0-24). This study will use a randomized single-blind controlled design to test the short-term (6 months) and long-term (an additional 18 months) impact of the intervention diets on symptoms of MS including QoL and related outcomes stated above. We will use a fourteen-day run-in period to identify participants who are most likely to be successful in completing study procedures; this process has been effective in our previous studies. Participants who successfully complete all baseline self-reported outcomes and follow all study procedures during the seven-day run-in period will be scheduled for an on-site baseline visit for randomization to one of three diets (time restricted olive oil based (TROO) ketogenic and modified Paleolithic elimination and Dietary Guidelines for America). On-site study visits will include blood draws, motor, cognitive, vision function assessments, and MRI. Motor assessments will include a 6-minute walk test, 25-foot walk test, 9-hole pegboard to test hand function, symbol digit exercise to test thinking functions, and critical flicker fusion test, ocular coherence tomography and low contrast vision sensitivity to test vision. The study participant will be escorted to the MRI unit to complete a non-contrast MRI of the brain. At the baseline visit, participants will be randomized. Participants assigned to the intervention diets will be given intervention specific educational materials including shopping lists, example menus and recipes, and the study supplements. Study participants randomized to the dietary guidelines for Americans diet will receive emails and/or text messages (approximately 3-6 weeks) to receive resources with websites for the Dietary Guidelines of America, and recent multiple sclerosis-related research that does not involve diet. Study team will provide fish oil, essential fatty acids, and phosphatidylcholine to the two intervention groups only. The participant will be scheduled for a Zoom video conference meeting with the assigned registered dietitian to review the assigned study diet. In addition, subjects will collect saliva specimens for microbiome analysis at each of the 3 site study visits (months 0, 3 and 24). Dietary History Questionnaire III will be completed at months 0, 3, 12 and 24 and will be used to assess adherence to the assigned dietary pattern. The online questionnaires sent to participants every 3 months will also be used to track supplement intake, medication use, and details about health \& life events, MS symptoms, fatigue, quality of life, doctor's appointment, and side effects they may be experiencing.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Enrollment
162
nutraceutical supplement
nutraceutical supplement
nutraceutical supplement
1. Complete elimination of all gluten-, dairy-, and egg-containing foods. 2. Increase fruit and vegetable intake to 6-9 servings/day comprising of 2-3 servings each of the following categories: intensely colored, sulfur-rich, and leafy greens. 3. Consume 6-12 ounces/day protein including organ meats and fatty fish. 4. Consume fermented foods daily. 5. Consume daily servings of algae, seaweed, and nutritional yeast.
1. Restriction of dietary carbohydrates to \< 50 grams/day. 2. Use olive oil (cold-pressed extra virgin preferred) to increase fat intake to \>160 grams/day. 3. Consume \<100 grams/day protein. 4. Limit dairy to 2 servings/day of whole fat options (completely exclude reduced fat dairy). 5. Consume at least 3 servings/day non-starchy vegetables.
1. Limit sodium to \< 2,300 mg/day. 2. Limit added sugar and saturated fat intake to \<10% of kcal/day, respectively. 3. Consume 5 servings of fruits and vegetables per day. 4. Consume 6-9 ounce equivalents/day of grains, making at least half whole grain options. 5. Consume 3 servings of reduced fat dairy per day. 6. Consume 6 ounces/day protein foods.
Univeristy of Iowa
Iowa City, Iowa, United States
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.
Time frame: baseline to 3 Months
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.
Time frame: baseline to 6 Months
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.
Time frame: baseline to 12 Months
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.
Time frame: baseline to 18 Months
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.
Time frame: baseline to 24 Months
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.
Time frame: baseline to 3 Months
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.
Time frame: baseline to 6 Months
Modified Fatigue Impact Scale (MFIS)
Change in MFIS survey questions, scores range from 0-84, lower score is better.
Time frame: baseline to 3 months
Modified Fatigue Impact Scale (MFIS)
Change in MFIS survey questions, scores range from 0-84, lower score is better.
Time frame: baseline to 6 months
Modified Fatigue Impact Scale (MFIS)
Change in MFIS survey questions, scores range from 0-84, lower score is better.
Time frame: baseline to 12 months
Modified Fatigue Impact Scale (MFIS)
Change in MFIS survey questions, scores range from 0-84, lower score is better.
Time frame: baseline to 18 months
Modified Fatigue Impact Scale (MFIS)
Change in MFIS survey questions, scores range from 0-84, lower score is better.
Time frame: baseline to 24 months
Hospital Anxiety Depression Scale (HADS)
Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence
Time frame: baseline to 3 months
Hospital Anxiety Depression Scale (HADS)
Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence
Time frame: baseline to 6 months
Hospital Anxiety Depression Scale (HADS)
Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence
Time frame: baseline to 12 months
Hospital Anxiety Depression Scale (HADS)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence
Time frame: baseline to 18 months
Hospital Anxiety Depression Scale (HADS)
Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence
Time frame: baseline to 24 months
Fatigue Severity Scale score (FSS)
Change in FSS survey question mean scores, scores range from 1-7, lower is better.
Time frame: Baseline to 3 months
Fatigue Severity Scale score (FSS)
Change in FSS survey question mean scores, scores range from 1-7, lower is better.
Time frame: Baseline to 6 months
Fatigue Severity Scale score (FSS)
Change in FSS survey question mean scores, scores range from 1-7, lower is better.
Time frame: Baseline to 12 months
Fatigue Severity Scale score (FSS)
Change in FSS survey question mean scores, scores range from 1-7, lower is better.
Time frame: Baseline to 18 months
Fatigue Severity Scale score (FSS)
Change in FSS survey question mean scores, scores range from 1-7, lower is better.
Time frame: Baseline to 24 months
Brain volume as measured by non contrast magnetic resonance imaging (MRI)
Change in MRI grey matter brain volume, more is better
Time frame: baseline to 24 months
Brain lesions as measured by non contrast magnetic resonance imaging (MRI)
Change in inflammatory lesions numbers as measured by non contrast brain MRI, fewer is better
Time frame: baseline to 24 months
Timed 25 foot walk test
seconds required to walk 25 feet, lower is better
Time frame: baseline to 3 months
Timed 25 foot walk test
seconds required to walk 25 feet, lower is better
Time frame: baseline to 24 months
9 Hole peg board test
seconds require to move 9 pegs to various locations on a peg board, fewer seconds is better
Time frame: baseline to 3 months
9 Hole peg board test
seconds require to move 9 pegs to various locations on a peg board, fewer seconds is better
Time frame: baseline to 24 months
Low contrast visual acuity
A measure of best corrected vision, measure is log minimal angle of resolution at 2.5% contrast. Lower number is better.
Time frame: baseline to 3 months
Low contrast visual acuity
A measure of best corrected vision, measure is log minimal angle of resolution at 2.5% contrast. Lower number is better.
Time frame: baseline to 24 months
Dietary History Questionnaire IIi
Change in dietary intake measured by survey questions
Time frame: baseline to 12 months
Dietary History Questionnaire IIi
Change in dietary intake measured by survey questions
Time frame: baseline to 3 months
Critical flicker fusion
change in The herz at which a flickering light is seen as non-flickering as measured by herz
Time frame: baseline to 3 months
Critical flicker fusion
change in The herz at which a flickering light is seen as non-flickering as measured by herz
Time frame: baseline to 24 months
Ocular Coherence tomography
Measure of optic nerve and retina depths using infrared light technology
Time frame: baseline
Ocular Coherence tomography
change in the Measure of optic nerve and retina depths using infrared light technology
Time frame: baseline to 3 months
Ocular Coherence tomography
change in the Measure of optic nerve and retina depths using infrared light technology
Time frame: baseline to 24 months
Neurofilament light chain
blood biomarker of neuroaxonal (brain) damage
Time frame: baseline to 3 months
Neurofilament light chain
blood biomarker of neuroaxonal (brain) damage
Time frame: baseline to 24 months
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.
Time frame: baseline to 12 Months
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.
Time frame: baseline to 18 Months
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.
Time frame: baseline to 24 Months